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Abstract: Mitochondria are subcellular organelles composed of two discrete membranes in the cytoplasm of eukaryotic cells. 
Th   ey have long been recognized as the generators of energy for the cell and also have been known to associate with several 
metabolic pathways that are crucial for cellular function. Mitochondria have their own genome, mitochondrial DNA (mtDNA), 
that is completely separated and independent from the much larger nuclear genome, and even have their own system for 
making proteins from the genes in this mtDNA genome. Th   e human mtDNA is a small (~16.5 kb) circular DNA and defects in 
this genome can cause a wide range of inherited human diseases. Despite of the signifi  cant advances in discovering the mtDNA 
defects, however, there are currently no eff  ective therapies for these clinically devastating diseases due to the lack of technology 
for introducing specifi  c modifi  cations into the mitochondrial genomes and for generating accurate mtDNA disease models. 
Th   e ability to engineer the mitochondrial genomes would provide a powerful tool to create mutants with which many crucial 
experiments can be performed in the basic mammalian mitochondrial genetic studies as well as in the treatment of human 
mtDNA diseases. In this review we summarize the current approaches associated with the correction of mtDNA mutations in 
cells and describe our own eff  orts for introducing engineered mtDNA constructs into the mitochondria of living cells through 
bacterial conjugation.
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phosphorylation (OXPHOS), which can be used to drive the 
important cellular reactions (Green & Reed, 1998; Saraste 
1999). Mitochondria are composed of two membranes with 
which two discrete compartments, the internal mitochondrial 
matrix space and the narrow intermembrane space, are 
structured (Frey & Mannella, 2000; Perkins et al., 2009). 
The outer membrane is permeable to molecules smaller 
than 5 kDa, making the intermembrane space chemically 
equivalent to the cytosol with respect to small molecules 
(Weissig et al., 2004). The inner membrane contains a high 
content of membrane proteins including components of the 
electron transport chain complexes as well as ATP synthase 
and a whole variety of transport proteins. Due to a unique 
lipid composition, the inner mitochondrial membrane 
is highly impermeable to any cellular molecules and this 
Mitochondrial genomes (mtDNA) and the 
complex genetics of mtDNA disorder 
Mitochondria are ubiquitous subcellular organelles, 
present in all eukaryotic cells. Although they are involved in 
several central metabolic pathways that are crucial for cellular 
function, their primary function is the conversion of food 
energy into chemical energy (ATP) through the oxidative Anat Cell Biol 43:97~109, 2010 Young Geol Yoon, et al 98
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impermeability can generate an imbalance in the distribution 
of protons (H
+) between the mitochondrial matrix and the 
intermembrane space. The chemical imbalance, i.e. proton 
gradient, is used for the driving force of ATP synthesis in 
mitochondria.
Mitochondria are generally thought to have arisen from 
an intracellular bacterial symbiont of the first ancestral 
eukaryotic cells, which presumably provided most of the 
energy metabolism for this symbiotic pairing (Gray et 
al., 1999). During the evolution of symbiotic relationship 
between these proto-bacteria and early eukaryotic cells, 
most of the genetic information from the circular proto-
bacterial genome (proto-mitochondrial genome) was either 
lost or was transferred to the nuclear genome of the host 
eukaryotic cells. Because the evolution of mitochondrial 
and nuclear genomes in various eukaryotic cells has been 
thought to occur simultaneously, the mitochondrial genomes 
of different eukaryotic lineages differ in size, gene content 
and even the genetic code that they use (Gray et al., 1999). 
Th   e modern mammalian mitochondrial genome is a circular 
DNA molecule that has been reduced to ~16.5 kb in size 
and encodes genes for only thirteen protein products, all of 
which are critical components of the electron transport chain, 
as well as two ribosomal RNAs and 22 transfer RNAs that 
are required for the mitochondrial translation system. All of 
the other genes needed for the biogenesis, maintenance and 
regulation of this organelle are encoded in the nucleus. Each 
of the genes encoded in the mitochondrial genome, however, 
remains critical for normal mitochondrial function (Wallace 
1999).
The human mitochondrial genome is a circular double 
stranded DNA molecule with a size of 16,569 bp (Fig. 1). 
The mtDNA has no intron but retains compactly arranged 
37 genes (13 proteins, 22 tRNAs and 2 rRNAs) critical for 
producing energy through OXPHOS. Major noncoding 
regions in the mtDNA genome involve the D-loop sequence 
and the origin of L-strand replication (OL), which controls 
mtDNA transcription and replication within mitochondria. 
Th   e 13 protein-coding genes encode subunits of the OXPHOS 
enzyme complexes. Seven polypeptides (ND1~ND6 and 
ND4L) are involved in subunits of complex I, one (cytochrome 
b) is part of complex III, three (COXI~COXIII) are in 
subunits of complex IV and two are part of ATP synthase 
(ATP6 and ATP8) (Scheffl   er 2001). Th   e remaining 24 genes 
(22 tRNAs and 2 rRNAs) encode the translational machinery 
of the mitochondrial genome itself. The mitochondrial 
genetic codes (mt) are similar to the nuclear codes (nu) but 
not exactly identical with them. Four codons are diff  erent in 
mammalian nuclear and mitochondrial translational system: 
AUA=Met (mt), Ile (nu); AGA, AGG =Stop (mt), Arg (nu); 
UGA=Trp (mt), Stop (nu). In addition to the diff  erent codon 
usages, mitochondria have some unique characteristics which 
reflect that the organelles are evolved from endosymbiotic 
proto-bacteria. The mitochondrial gene expression system 
still carries hallmarks of its bacterial ancestor (Wallace 1999; 
2007). For example, an N-formylmethionyl-tRNA (fMet-
tRNA) which is involved in the initiation of protein synthesis 
in bacteria is employed as initiator of protein synthesis in 
mitochondria (Galper & Darnell, 1969; Epler et al., 1970).
It is now well known that mutations in the mitochondrial 
genome can cause a wide range of human diseases (Wallace 
1999). Mutations in human mitochondrial genome were 
first reported in 1988. Wallace et al. (1988) demonstrated 
that a nucleotide change in a mitochondrial DNA energy 
production gene (NADH dehydrogenase subunit 4, ND4) 
can result in a neurological disease, Leber's hereditary optic 
neuropathy (LHON). Furthermore Holt et al. (1988) found 
deletions in muscle mitochondrial DNA from patients 
with mitochondrial myopathies. Within a decade, over 100 
Fig. 1. Schematic representation of the human mitochondrial genome. 
Th   e genome encodes two ribosomal RNAs (12S and 16S), 22 transfer 
RNAs (indicated by single letter abbreviation) between the coding 
genes, and 13 essential genes that encode subunits of the oxidative 
phosphorylation enzyme complexes. The major noncoding regions 
in the genome are the D-loop region which includes heavy and 
light-strand promoters (HSP and LSP), and the origin of L-strand 
replication (OL). Mammalian mitochondrial genome engineering
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pathogenic point mutations as well as multiple deletions and 
rearrangements involving essentially every mitochondrial 
gene had been described (DiMauro & Schon, 2001). Human 
diseases related with defective mitochondrial function exhibit 
a broad array of clinical problems and often involve tissues 
that have high energy requirements, such as heart and other 
muscle and the endocrine and nervous systems (Wallace 
1999). Typically a single mitochondrial mutation leads to a 
complex medical syndrome, with clinical features that may 
include such problems as muscle deprivation and frailty, 
vision loss, ataxia, stroke-like episodes, cardiomyopathy, 
seizures, and hearing loss. The close causal relationship 
between accumulation of mtDNA mutations and age-
related functional loss is evident in a mouse model of 
hyper-mutated mitochondrial DNA that was induced by a 
proof-reading-deficient version of the mitochondrial DNA 
polymerase γ (Trifunovic et al., 2004; Edgar et al., 2009). 
These mutants exhibit accelerated accumulation of mtDNA 
mutations, increase of heart weight, enlarged mitochondria 
and the phenotype of kyphosis, alopecia, osteopenia, loss 
of body mass, anemia, lipodystrophy, cardiomyopathy and 
reduced fertility. Heart muscle tissues from these mtDNA-
mutator mice have a mosaic pattern, with cytochrome c 
oxidase deficiency, which is normally found in the ageing 
human heart (Trifunovic et al., 2004). In addition to those 
diseases in which a mitochondrial genome mutation is the 
primary cause of the disease, there is also a growing body of 
evidence that abnormal mitochondrial function plays a role 
in the pathology of many other diseases as well, including 
Huntington’s Disease (Panov et al., 2002), Alzheimer’s Disease 
(Castellani et al., 2002) and even cancer (Clark et al., 2002).
Although the mammalian mtDNA genome has been 
amenable to many of the standard molecular techniques 
used to study the nuclear genome (Yoon & Koob, 2003), no 
practical method has yet been developed to introduce muta-
genized mtDNA directly and stably into the mitochondria of 
a mammalian cell. Genetic manipulation of mitochondrial 
genome and its gene products is also one of the approaches 
under investigation for the treatment of mtDNA disorders. 
Yeast mitochondria can be transformed with exogenous 
DNA using a biolistic procedure (Fox et al., 1988; Johnston 
et al., 1988), but to date this method has been limited to 
the transformation of mitochondria in yeast and closely 
related organisms. This technical roadblock is preventing 
many important experiments from being performed in the 
field of mammalian mitochondrial genetics, and as a result 
mitochondrial transformation has long been viewed as the 
“holy grail” of this fi  eld (Shoubridge 2000). 
In this review we conduct a breif overview of the current 
progress in manipulating mammalian mitochondrial genomes 
using mtDNA delivery systems and other approaches. The 
ability to modify the mitochondrial genomes would provide 
a powerful tool to create mutants with which many crucial 
experiments can be performed to advance our knowledge in 
the fi  eld of mitochondrial genetics as well as to develop ways 
of treating human mtDNA diseases. At the end of this review, 
we summarize our own efforts for introducing engineered 
mtDNA constructs into the mitochondria of living cells 
through bacterial conjugation.
Current approaches of modifying mitochondrial 
genomes in mammalian cells
Mammalian mitochondrial transformation with exogenous 
DNA molecules is a complex fi  eld of mitochondrial research 
and is still in early stages. Although many efforts were 
undertaken during the last decade and promising in vitro 
experimental results were reported, no one can generate 
transformed cells with modifi  ed or engineered mitochondrial 
genomes in their mitochondrial networks. Introducing 
exogenous DNA including re-engineered mitochondrial 
genomes has proven to be more challenging than strategies 
directed at the nuclear genome. In the following sections, 
we discuss diff  erent approaches towards the modifi  cation of 
mitochondrial genomes through direct subcellular disposition 
of nucleic acids and/or modifying proteins.
Transferring nucleic acids directly by conjugating 
with mitochondriotropic molecules 
Lipophilic cationic compounds have amphiphilic charac-
teristics with delocalized positive charges. Positively charged 
hydrophobic molecules have tendency to form amphipathic 
helices which could pass through mitochondrial membranes 
and acculmulate in the mitochondria matrix (Hashimoto 
et al., 1984; Rottenberg 1984). Because mitochondria have 
highly negative membrane potential, cationic molecules 
such as rhodamin 123 (Chen et al., 1982) and ethidium 
bromide (Nass 1970) which are commonly used to visualize 
mitochondria and to deplete mtDNA, respectively, are 
attracted to negatively charged mitochondria. 
One of lipophilic monocation, triphenylphosphonium Anat Cell Biol 43:97~109, 2010 Young Geol Yoon, et al 100
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(TPP), can pass through phospholipid bilayers and 
accumulate in negatively-charged mitochondrial matrix. 
This unique characteristic of TPP is specifically used to 
deliver small therapeutic molecules such as antioxidants 
ubiquinone and vitamin E to mitochondria (Smith et al., 
2003; Ross et al., 2006). TPP-facilitated delivery of peptide 
nucleic acids (PNA) has also been investigated in an antisense 
mitochondrial gene therapy system (Muratovska et al., 2001). 
PNA is a synthetic DNA-like polynucleotide in which each 
nucleotide is connected by a polyamide backbone (peptide 
bond), rather than by deoxyribose phosphodiester subunits 
(Nielsen et al., 1991) and can stably form double strands with 
complementary DNA or RNA molecules. PNA conjugated 
with TPP can cross the mitochondrial membranes and 
selectively suppress mtDNA replication by binding to the 
complementary DNA sequences. An in vitro model has shown 
that TPP conjugated PNA exclusively hampers the replication 
of mtDNA containing the A8344G point mutation, which 
causes the human mtDNA disease 'myoclonic epilepsy and 
ragged red fibrs' (MERRF) but not the wild-type sequence 
that differs at a single nucleotide position (Muratovska et 
al., 2001). Since mitochondrial genomes are maintained as 
multicopy status and wild type and mutant mtDNA coexist in 
many patients with defective mitochondrial function, selective 
inhibition of mutant mtDNA replication would be required 
for the treatment of the mitochondrial disease. Therefore 
therapeutic potential of this antisence PNA gene therapy must 
be the sequence-specific and selective inhibition of mutant 
mtDNA in mitochondria. However, in an in vivo model with 
the MERRF mtDNA, TPP-PNA conjugates did not selectively 
inhibit replication of mutant mtDNA even though they were 
accumulated several hundred-fold into the mitochondria. 
One possible explanation is that any single-stranded mtDNA 
present during mtDNA replication is unavailable for binding 
to complementary PNAs. This could occur because binding 
is prevented by proteins associated with the DNA, or because 
the lifetime of the single-stranded DNA is insufficient 
(Muratovska et al., 2001). This hurdle may be overcome by 
designing PNA oligomers that can bind specific double-
stranded DNA sequences to form a stable triple helix. 
DQAsomes are mitochondriotropic bolasomes that are 
derived from the compound dequalinium (Weissig et al., 
1998). Dequalinium is a dicationic compound resembling 
bolaform electrolytes and is a symmetrical molecule with 
two charge centers separated at a relatively large distance. 
This symmetric bipolar compound can self-associate into 
mechanically very stable spherical monolayer aggregates 
(called DQAsomes) upon sonication in aqueous medium. 
DQAsomes have been observed to migrate and localize 
with mitochondria within living cells (Weissig et al., 1998; 
Weissig & Torchilin, 2000; D’Souza et al., 2003). These 
liposomal-like vesicles are capable of binding plasmid DNA 
and form DQAsome-DNA complexes in which the plasmid 
DNA is protected from nucleases. DQAsomes have been 
employed to deliver both oligonucleotides and plasmid 
DNA conjugated with a mitochondrial targeting sequence 
(MTS) to mitochondria of living cells (D’Souza et al., 2005). 
Although DQAsome-DNA complexes can approach to 
mitochondria inside the living cells and colocalize with a 
mitochondrial-specific dye, MTS conjugated with DNA 
was not sufficient to assist DNA internalization into the 
matrix space (D’Souza et al., 2005). Nevertheless DQAsomes 
may be used to deliver functional recombinant mtDNA 
construct to mitochondria. As the full recombinant mtDNA 
clones are now available and conventional drug resistance 
proteins (aminoglycoside phosphotransferase  (Neo
R) 
and hygromycin B phosphotransferase (Hyg
R)) present in 
mitochondria are functional and confers resistance to high 
levels of G418 (aminoglycoside antibiotic) and hygromycin 
(Yoon & Koob, 2003; 2008; Yoon et al., 2009), DQAsomes-
mtDNA complexes with and without a drug resistance gene 
could serve as effective mediators for mtDNA transfer into 
the mitochondrial network of wild type tissue culture cells 
and mtDNA-less ρ
0 cells, respectively. DQAsomes deliver 
recombinant mtDNA construct at the site of mitochondria 
in cells, and by an effective DNA import mechanism 
such as the mitochondria natural import competence 
(Koulintchenko et al., 2006), the mtDNA construct may be 
introduced into mitochondrial matrix where the DNA can 
be properly replicated and transcribed. Weissig group also 
investigated mitochondriotropic liposomes by linking the 
TPP cation into conventional liposomes (Boddapati et al., 
2005). The phospholipid vesicles (liposomes) are rendered 
mitochondrial-specific by modifying the liposomal surface 
with TPP and the modified liposomes seem to accumulate 
at or near the site of the mitochondria. However, these 
mitochondriotropic liposomes show high level of cytotoxicity 
when applied in tissue culture cells (Boddapati et al., 2005). 
The cytotoxicity may have resulted from direct contact 
or association of the mitochondriotropic liposomes with 
mitochondrial membranes and consequently this interaction 
may induce channel formation, which initiates an apoptotic Mammalian mitochondrial genome engineering
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chain reaction from the damaged mitochondria. 
Transferring nucleic acids through conjugating 
mitochondrial targeting sequences (MTS) 
Among ~1,500 mitochondrial proteins which 
participate mitochondrial biogenesis including the oxidative 
phosphorylation, only 13 proteins are encoded from the 
mitochondrial genome and the rest of the mitochondrial 
proteins are expressed from the nuclear genome and actively 
transported to the mitochondria. These mitochondrially 
transported proteins contain leader sequences which direct 
molecules to the mitochondria. Typically matrix targeting 
sequences are 10~80 amino acids in length, are generally 
have the ability to form amphipathic helices (von Heijne 1986; 
Mukhopadhyay et al., 2003). The MTS is recognized by the 
mitochondrial import complexes (translocases of the outer 
membrane (TOM) and the inner membrane (TIM)) and 
mediates mitochondrial localization, and subsequently deliver 
mitochondrial proteins to the matrix compartment. Th  us,  the 
MTS and mitochondrial protein import complexes have been 
explored for nucleic acids import to mitochondria.
In an early study, mitochondrial import of a single-
stranded or double-stranded 24-bp piece of DNA was 
shown by covalently conjugating the DNA with the MTS 
of yeast cytochrome oxidase (Vestweber & Schatz, 1989). 
The Mitochondrial import of chemically synthesized signal 
peptides and their conjugates to small single- and double-
stranded DNA have also been investigated using isolated rat 
liver mitochondria (Seibel et al., 1995; Lu & Beavis, 1997). 
Among these experiments, Seibel et al. (1995) confirmed 
that the leader sequence conjugated to double stranded 
DNA molecule of a 17 or 322 bp in size was imported to 
the mitochondrial matrix by utilizing the protein import 
pathway. They also suggests that the translocation of MTS-
conjugated DNA is independent from the size of its passenger 
DNA and that comparatively large DNA molecules over 
322 bp could possibly be imported to mitochondria by 
attaching to MTS. The mitochondrial targeting sequence 
has also been conjugated to a PNA complementary to 
a portion of the mtDNA sequence (Flierl et al., 2003). 
This targeting peptide-PNA (MTS-PNA) conjugate was 
annealed to an oligonucleotide complementary to the PNA 
sequence and then the complex was transferred into the 
cytosol using commercially available cationic liposome 
formulations. This procedure efficiently delivered the 
oligonucleotides into the mitochondrial matrix. In another 
approach, an oligonucleotide was coupled covalently to a 
mitochondrial targeting peptide sequence and then the MTS-
oligonucleotides were encapsulated with a cationic liposome 
(Geromel et al., 2001). Th  ese  modifi  ed MTS-oligonucleotides 
complexed to liposomes have been shown to enter the 
cytoplasm of cells, dissociate from the complexes, and then 
penetrate into the mitochondria of primary cultured cells. 
The use of MTS is considered to be the most promising 
candidate for the delivery of DNA to mitochondria when 
complexed with cationic liposomes including DQAsomes 
(D’Souza et al., 2005). However, the experiments performed 
previously used oligonucleotides or relatively small linear 
DNA fragments to transport into mitochondria. Although 
MTS peptides actively contribute to a mitochondrial targeting 
eff  ect and subsequently mediate the transport of the complex 
across the mitochondrial membranes, the remaining question 
is that whether conjugated MTS peptide could deliver a 
large circular DNA molecule such as recombinant mtDNA 
constructs to mitochondria. Th   is question should be answered 
because a mitochondria-specifi  c delivery system requires an 
efficient delivery of circular DNA to mitochondria for the 
purpose of modifying or manipulating DNA in mitochondria 
of living cells.
Transferring nucleic acids using polyethylenimine 
(PEI) polymer  
Direct DNA delivery to the mitochondrial matrix has 
been investigated with MTS-conjugated PEI (MTS-PEI) (Lee 
et al., 2007). PEI is a polymeric transfection agent that has 
been widely used for gene delivery to the nucleus including 
circular plasmid vectors. It has a high positive charge density 
and therefore PEI and DNA can create condensed positively 
charged particles which, in turn, bind to anionic cell surface 
residues and are brought into the cell via endocytosis. MTS-
PEI has been shown to form complexes with DNA equally 
well as shown in PEI itself. When applied in a living cell, 
MTS-PEI can transport DNA into mitochondrial sites, 
indicating that the DNA delivery to mitochondria using MTS-
PEI could be a feasible approach. However several important 
questions regarding this PEI polymer as a mitochondrial 
delivery vector remain to be answered. First, DNA should 
be released from the MTS-PEI complexes when they arrive 
to the mitochondrial site. Th   e dissociation of the MTS-PEI/
DNA complexes allows DNA to be freed and allows it to be 
imported into the mitochondria. In spite of many efforts 
to address this question, it is not yet clearly demonstrated Anat Cell Biol 43:97~109, 2010 Young Geol Yoon, et al 102
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which step enables the release of DNA from the PEI/DNA 
complexes. Second, it has not been addressed whether MTS-
PEI/DNA complexes are internalized into the mitochondrial 
matrix or bound to the surface of the mitochondrial 
membrane. If the MTS-PEI binds to mitochondrial 
membrane and induces channel formation on the outer 
mitochondrial membrane, cytochrome c may be released into 
the cytosol, which would force cells to enter apoptosis. If this 
is the case, subtle control of working concentration of PEI 
complexes should be determined to minimize cytotoxicity to 
cells. 
Transferring recombinant mtDNA constructs through 
electroporation and natural import competence 
Several pioneering efforts of introducing exogenous 
circular plasmid DNA physically into mitochondria have 
been demonstrated. Collombet et al. (1997) first described 
the transfer of small 7.2-kb recombinant plasmids into 
isolated mouse mitochondria by electroporation and proved 
the functional integrity of the electroporated mitochondria 
using enzymatic assays. Subsequently Yoon & Koob (2003) 
optimized the electroporation conditions for introducing a full 
mitochondrial genome construct using mitochondria isolated 
from mtDNA-defi  cient mouse ρ
0 cells and demonstrated the 
biological activity of the recombinant mouse mitochondrial 
genomes by detecting in organelle RNA expression through 
an RT-PCR assay specifi  c for transcripts from the transferred 
DNA. Th   e basic idea of these approaches is that the modifi  ed 
mtDNA construct is introduced into isolated mitochondria 
by electroporation and then the electroporated mitochondria 
are transferred into zygotes or tissue culture cells through 
a microinjection technique to transfer engineered mtDNA 
constructs. Current microinjection technique allows for the 
introduction of isolated mitochondria into a living cell. Th  e 
injected mitochondria can lead to a rapid replacement of the 
endogenous mitochondrial DNA in cells (King & Attardi, 
1988; 1989). However, the harsh experimental conditions 
required for electroporation appear to cause irreversible 
damage to the structural integrity of the mitochondria and 
kill mammalian cells when applied to whole cells (Yoon & 
Koob, 2005). As an interesting alternative method, the natural 
import competence of isolated mammalian mitochondria for 
DNA has been demonstrated (Koulintchenko et al., 2006). 
This study showed that naked DNA can be spontaneously 
imported into the isolated mitochondria when the DNA and 
the mitochondria are mixed and that the imported DNA 
could be used as a substrate for DNA synthesis and promoter-
driven transcription, with the resultant polycistronic 
RNA being processed and excised mt-tRNA matured 
(Koulintchenko et al., 2006). Although in vivo phenomenon 
of this natural competence of naked DNA into mitochondria 
has not been reported, the authors noted that in vivo DNA 
transport to mitochondria may be feasible in combination 
with cationic liposomes such as DQAsomes (see above). 
Cationic liposomes associate with DNAs and condense them 
into DNA-liposome complexes, which are able to access to 
cytosol and localize in mitochondria. If the DNA is released 
efficiently from these DNA-liposome complexes near the 
mitochondrial site, the freed DNA might spontaneously 
be imported into the mitochondrial networks through this 
natural import competence (Koulintchenko et al., 2006).
Modulating mtDNA content by mitochondrially 
targeted restriction endonucleases 
Patients with mitochondrial DNA disease usually harbor 
a mixture of mutant and wild-type mtDNA, which is termed 
heteroplasmy. The clinical features of the mtDNA disease 
depend on the percentage of mutant mtDNA (the ‘mutation 
load’) in vulnerable tissues. Several studies have shown that 
there is a threshold whereby a certain level of mutant mtDNA 
is necessary before the disease becomes biochemically and 
clinically apparent (Thorburn & Dahl, 2001; DiMauro & 
Schon, 2003). To modulate mutant mtDNA levels in living 
cells, mitochondrially targeted restriction endonucleases 
have been used (Srivastava & Moraes, 2001; Tanaka et al., 
2002). Based on the presence of mtDNA in a heteroplasmic 
state, Srivastava & Moraes (2001) and Tanaka et al. (2002) 
demonstrated experiments manipulating mutant mtDNA 
content by a mitochondrially targeted PstI and SmaI (MTS-
PstI and MTS-SmaI), respectively. Mutant mtDNA is 
selectively destroyed or its replication is inhibited by the 
endonuclease and thereby only wild-type mtDNA propagate 
in the mitochondria. Recently, a heteroplasmic T8993G 
mutation which is a cause for the NARP and MILS syndromes, 
has also been selectively removed by the mitochondrially 
targeted R.XmaI restriction endonuclease (Alexeyev et al., 
2008). This restriction endonuclease approach, however, is 
relatively limited in terms of the range of mutations that can 
be targeted. Not all mutations will produce a restriction site 
and even though a site is generated, it may not be unique, and 
hence would digest wild-type mtDNA molecules. To solve 
this problem, the selective degradation of mutated mtDNA Mammalian mitochondrial genome engineering
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molecules has been tested using zinc-fi  nger proteins (ZFPs) 
(Minczuk et al., 2008). Zinc finger technology allows for 
the engineering of zinc-finger proteins that can bind any 
predetermined DNA sequence (Kim et al., 1996; Wu et al., 
2007). Fusing a particular ZFP to a nuclease domain creates 
a zinc-finger nuclease (ZFN) that can cleave DNA adjacent 
to the specific ZFP-binding site. By designing a single-
chain quasi-dimeric ZFN with predetermined DNA binding 
domain, ZFN could recognize a pathogenic point mutation in 
mtDNA, selectively cleave and eliminate the mutated mtDNA 
and thereby increase the proportion of wild type mtDNA in 
the cells (Minczuk et al., 2008). ZFN technology therefore 
could provide a powerful tool to modulate heteroplasmy for 
treating disease caused by mtDNA point mutations.
Mitochondrial gene replacement therapy using 
protein transduction 
Recently, a novel protein transduction technology 
(protofection) that would allow insertion and expression of 
mitochondrial genomes into living cells has been reported 
(Khan & Bennett, 2004; Keeney et al., 2009). Protofection 
uses recombinant human mitochondrial transcription 
factor A (TFAM) engineered with an N-terminal protein 
transduction domain (PTD) followed by the MTS to deliver 
mtDNA cargo to the mitochondria of living cells. Since 
TFAM is the major mtDNA-binding protein with two high-
mobility group (HMG) domains, it binds to and organizes 
mtDNA into a mitochondrial nucleoid structure, which is 
necessary for mtDNA transcription and maintenance (Parisi 
& Clayton, 1991; Alam et al. 2003). Therefore the MTD-
TFAM (MTD = PTD+MTS = mitochondrial transduction 
domain) recombinant protein would bind mtDNA by 
interacting with TFAM and rapidly transport it across plasma 
membranes to mitochondria with the assistance of MTD. For 
therapeutic purposes, protofection technology has been tested 
in Parkinson's disease (PD) cybrid model cells by combining 
MTD-TFAM with wild type mtDNA (Keeney et al., 2009). 
Typically PD cybrids show impaired respiration and a reduced 
mtDNA level, but when the PD cybrid cells were treated 
with the MTD-TFAM/wild type mtDNA mixture the cells 
showed increased mtDNA copy numbers, mtDNA-derived 
RNA levels, TFAM and electron transport complex proteins, 
cell respiration, and physical mitochondrial movement, 
which suggested the possibility of therapeutic application 
of protofection technology to mtDNA diseases. However 
this approach requires additional experiments to identify 
the molecular mechanisms whether the therapeutic effect 
is derived from the wild type mtDNA that was exogenously 
transferred and this protein transduction technology should 
be reproducible by other investigators.
A novel approach to re-engineer mitochon-
drial genomes through bacterial conjugative 
transfer of plasmid DNA into mitochondria
As for a unique approach, we have transferred exogenous 
plasmid DNA successfully into the mitochondrial matrix by 
means of conjugation between bacteria and mitochondria 
(Yoon & Koob, 2005). Because conjugation is a relatively 
gentle process, this type of procedure would enable the transfer 
of large DNA constructs into mammalian mitochondria 
without damaging their structural integrity. Typically the 
bacterial conjugation process is driven entirely by molecular 
machinery in the donor bacterial cell (Waters 1999) and it is 
now well known that a broad range of cell types can serve as 
the DNA recipient, including yeast (Heinemann & Sprague, 
1989; Nishikawa & Yoshida, 1998), plants (Piers et al., 1996) 
and even mammalian cells (Kunik et al., 2001; Waters 2001). 
Because mitochondria arose from an intracellular bacterial 
symbiont of the first ancestral eukaryotic cells (Gray et al., 
1999) and have inner and outer membranes that are generally 
similar to many bacteria, it is perhaps not surprising that the 
bacterial conjugation system can transfer DNA constructs 
into mitochondria as well (Yoon & Koob, 2005).
In order to determine whether bacterial conjugation could 
serve as an eff  ective means of transforming mitochondria, an 
assay system was designed to specifi  cally detect DNA that was 
transferred into the matrix of structurally intact mitochondria 
(Yoon & Koob, 2005). In this assay, the transferred DNA is 
transcribed by an RNA polymerase that is present only in the 
mitochondrial matrix and these transcripts are specifically 
detected by RT-PCR. Any DNA or RNA outside of the 
mitochondria is eliminated by specifically lysing the E. coli 
donor cells and adding high levels of DNase and RNase prior 
to in organelle RNA isolation. Although this assay could 
perhaps have been performed by placing a mitochondrial 
promoter on the mobilizable DNA construct and relying 
on the endogenous mitochondrial RNA polymerase to 
generate transcripts from transferred DNA, we instead chose 
to use the phage T7 transcription system because T7 RNA 
polymerase can provide robust RNA transcription from Anat Cell Biol 43:97~109, 2010 Young Geol Yoon, et al 104
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the DNA template and is well-characterized through many 
experiments. In order to adapt this conjugative DNA transfer 
system to the transformation of mitochondrial networks 
within living cells, we employed a conjugative E. coli strain 
that is capable of invading the cytoplasm of mammalian cells. 
Th   e overall experimental scheme is shown in Fig. 2. Lim et al. 
(2008) have shown that the bacterial conjugation machinery 
is functional in the cytoplasm of mammalian cells. Specially 
constructed invasive E. coli was able to escape from the 
phagocytic vacuole and transfer a conjugative plasmid at high 
frequency to a recipient E. coli that was invaded separately 
(Lim et al., 2008). Th   erefore a conjugative and invasive strain 
of E. coli could be used as a delivery vehicle for transferring 
DNA into the mitochondrial networks of mammalian tissue 
culture cells.  
Making a non-replicating but metabolically active 
(conjugative) E. coli strain 
Since this experimental system requires invasive nature 
of E. coli, we employed a clinical isolate of an enteroinvasive 
E. coli (EIEC). This strain can invade and replicate in the 
cytoplasm of both mouse and human tissue culture cells 
when we tested the EIEC strain by gentamicine protection 
assay (Sinai & Bavoil, 1993) (Fig. 3). Typically, gentamicin 
applied to the culture medium kills any bacteria outside of the 
cultured cells and thus only the E. coli invading the cytoplasm 
are protected from the antibiotic. The tissue cultured cells 
are then lysed and the lysates are spreaded on LB medium to 
verify the viable E. coli (Fig. 3). To enable this strain to serve 
as a conjugative DNA donor, we introduced a conjugative 
“helper plasmid” into this strain and confirmed that the 
resulting strain could transfer DNA into other E. coli strains. 
Th   is initial strain, however, quickly replicates in the cytoplasm 
of tissue culture cells and kills them (see Fig. 3, upper panel). 
To alleviate this problem, we removed the gene of the E. coli 
chromosomal replication initiation protein dnaA (Sutton & 
Kaguni, 1997) and transferred it onto a plasmid that replicates 
at a low temperatures (30
oC) but not at a high temperature 
(42
oC) (Fig. 4A). Th   is system allowed us to culture this strain 
Fig. 2. Experimental scheme for 
transferring engineered mtDNA 
constructs into the mitochondrial 
networks of mammalian cells by 
bacterial conjugation. The circular 
mouse mtDNA genome is isolated from 
mouse liver and cloned in E. coli. The 
E. coli is modified to contain invasive 
and conjugative ability. Th  e  E. coli then 
invades the cytoplasm and conjugatively 
transfers the mtDNA construct to the 
mitochondrial networks of the cell. 
The cells that the engineered mtDNA 
construct is incorporated in their 
mitochondria are then used to generate 
mouse models of human mitochondrial 
diseases.
Fig. 3. Invasive E. coli. The arrows indicate invaded E. coli into the 
cytoplasm of a cell. Th  is  invasive  E. coli occupies the entire cytoplasm 
of the cell and eventually kills the cell. The lower panel shows the 
gentamicine protection assay. Typically gentamicin that is applied to 
the culture medium kills any bacteria outside the tissue culture cells and 
only bacteria that have invaded into the cytoplasm are protected from 
the antibiotic. The EIEC strain that has been invaded into the cells 
was able to form many colonies aft  er gentamicin treatment whereas in 
the control plate only a background level of colonies formed when the 
laboratory strain of E. coli DH5α was applied to tissue culture cells. Mammalian mitochondrial genome engineering
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at a low temperature and then to shift   to a high temperature 
in order to generate a population of non-replicating but 
metabolically active (conjugative) daughter cells. Th  ese  non-
replicating and conjugative daughter cells could be readily 
separated from any remaining replication-competent parent 
cells. Th  e  replicating  E. coli cells could be selectively removed 
from the culture by lysing the cells using antibiotics such as 
ampicillin. Beta-lactam antibiotics including ampicillin exert 
their bactericidal effects by inhibiting the cross-linking step 
(transpeptidation) of bacterial cell wall biosynthesis, resulting 
in cell lysis (Waxman & Strominger, 1983). During this 
incubation, therefore, only the non-replicating E. coli remains 
intact and the replicating one is lysed by ampicillin. When we 
tested the replication ability of ampicillin-treated (+Amp) 
or non-treated (-Amp) E. coli on LB plates (Fig. 4B, plates 1 
and 2), no colony formed in the ampicillin-treated cultures 
(Fig. 4B, plate 2). When we tested the conjugation ability of 
the ampicillin-treated EIEC by mating them with recipient 
E. coli DH5α, we found that the recipient cells were able to 
grow on selection medium (Fig. 4B, plate 4), indicating the 
non-replicating EIEC is capable of donating plasmid DNA 
containing a selectable marker to a recipient E. coli strain. 
These results revealed that a population of non-replicating 
but metabolically active (conjugative) E. coli can be obtained 
using temperature and antibiotic treatment.
Invasion of non-replicating E. coli into mammalian 
tissue culture cells 
Since a population of non-replicating E. coli cells can be 
separated by controlling temperature and treating ampicillin, 
we next tested whether these non-replicating forms of E. coli 
could still actively invade the cytoplasm of tissue culture cells 
(Fig. 4C). Because these E. coli could not form any colonies, 
we assayed the invasion of non-replicating E. coli by labeling 
them with GFP and visually confi  rmed that they were present 
in the cytoplasm of the cells in the invaded cultures. Note 
that the non-replicating E. coli are more elongated than the 
replicating forms due to continued cell growth in the absence 
of genomic DNA replication. Th   e size of the E. coli shown in 
Fig. 4C, which is roughly four times the length of the rapidly 
dividing cells, is typical of the cell length in non-dividing 
cultures. However the number of non-replicating E. coli 
invading the cytoplasm decreased compared to the wild type 
EIEC strain. We, however, signifi  cantly improved the number 
of E. coli that can invade the cytoplasm of tissue culture cells 
by adding the invasin gene from Yersinia pseudotuberculosis 
(Grillot-Courvalin et al., 1998) into our conditionally 
replicating EIEC bacterial strain (Fig. 4D). Th  e  invasin  surface 
protein binds to cell-adhesion proteins on the tissue culture 
cells and enhances phagocytosis. Fig. 4D shows a single tissue 
culture cell photographed aft  er invasion with a GFP labeled, 
non-replicating population of these invasive E. coli. Nearly 
100% of invasion effi   ciencies was achieved with this modifi  ed 
strain, while still retaining viability in most of the invaded 
tissue culture cells using ampicillin to eliminate all of the 
replicating EIEC bacteria from the cultures prior to invasion. 
In the bacterial conjugative DNA transfer approach shown 
in Fig. 2, we used E. coli as an mtDNA delivery vector aft  er 
providing invasive and conjugative characteristics. Since 
the invasiveness of this E. coli strain has been evaluated, the 
conjugation process of the strain between mitochondria and E. 
coli should be defi  ned in a cytoplasmic environment of cells. 
It would be informative to use T7 tissue culture cell lines in 
Fig. 4. Characterization of modifi  ed E. coli. (A) Temperature sensitive 
EIEC strain. This E. coli can grow at a lower temperature (30
oC) 
whereas is not able to replicate at a higher temperature (42
oC). (B) 
Generation of a population of a non-replicating but metabolically 
active (conjugative) EIEC daughter cells by temperature and antibiotic 
(ampicillin) treatment. Non-replicating EIEC donor cells (see plate 
2) can actively conjugate with the recipient cells and transfer DNA 
with which the recipient DH5α can grow on the selection plate (see 
plate 4). (C)  Non-replicating EIEC are still able to actively invade 
the cytoplasm of tissue culture cells. Note that the non-replicating E. 
coli are more elongated than the replicating forms. (D) Invasiveness 
of the non-replicating EIEC was improved by adding the invasin gene 
from Yersinia pseudotuberculosis. Multiple non-replicating bacteria that 
invaded in the cell are shown by GFP labeling. Anat Cell Biol 43:97~109, 2010 Young Geol Yoon, et al 106
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which T7 RNA polymerase is targeted to the mitochondria 
and a mobilizable mtDNA construct that contains a T7 
promoter along with a fluorescent marker (GFP or DsRed) 
gene. Once the invasive, non-replicating and conjugative EIEC 
strains have delivered the T7 constructs into the mitochondria 
of T7 cell lines in which the T7 RNA polymerase is already 
targeted, we may be able to observe the fluorescence 
expression from these mitochondrial networks through the 
strong T7 expression system. Because single stranded DNA 
is typically transferred by bacterial conjugation, an mtDNA 
construct can be designed to spontaneously form a double 
stranded hairpin structure containing a transcriptionally 
active dsDNA T7 promoter sequence when the plasmid is 
transferred to the mitochondria by conjugation (Yoon & 
Koob, 2005). The fluorescent protein expression from this 
construct, therefore, is a direct indicator of transfer of the 
DNA construct into the mitochondrial matrix and is not 
dependent on uncharacterized secondary events, such as 
DNA replication. In addition, because the conjugative process 
is fairly nonspecifi  c, we could increase the specifi  city of this 
reaction for mitochondrial transfer by expressing peptides 
on the surface of the E. coli (Becker et al., 2005) that are 
known to bind to the mitochondrial outer membrane (e.g., 
Mfn1) (Legros et al., 2002). Because mitofusin is required for 
the initial tethering between adjacent mitochondria before 
mitochondrial fusion, the protein would facilitate E. coli to 
search and attach to the mitochondrial membrane in the 
cytoplasm.
Perspectives
MtDNA mutations and subsequent mitochondrial 
dysfunction in cells are clearly related with a wide range of 
inherited human diseases. Although discovering mtDNA 
mutations that are involved in clinically devastating diseases 
has advanced significantly, there are currently little or no 
available therapies to treat mtDNA diseases due to the lack 
of technology for introducing modified mitochondrial 
genomes into the mitochondria of living cells. The current 
strategy for mitochondrial genome therapies is mainly 
focused on selectively inhibiting mutant mtDNA using 
antisense molecules or a restriction enzyme and thus can 
modulate mutant mtDNA levels in cells. Deliverying of 
circular DNA constructs, however, would provide a new 
and invaluable tool to genetically engineer mitochondrial 
genomes in mammalian cells, which could provide further 
understanding of mitochondrial function and treatment of 
human mitochondrial diseases. 
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